Media Details

  • Home
  • Media
  • Details
  2020-09-09 15:55:44

Ho Wah Genting Berhad enters into MOU with XKX to manufacture COVID-19 vaccine prevention

KUALA LUMPUR, 09 SEPTEMBER 2020 – Ho Wah Genting Berhad’s (“HWGB” or the “Company”) (Bursa Stock Code:9601) wholly-owned subsidiary, HWGB Biotech Sdn Bhd (“HWGB Biotech”) [formerly known as HWG Consortium Sdn Bhd], has entered into a Memorandum of Understanding (“MoU”) with Xinkexian (Beijing) Biotechnology Co., Ltd (“XKX”) to explore the appointment of XKX as a non-exclusive manufacturer to produce Vaccines upon successful completion of the research and development of vaccines, immunological treatment and diagnostic product development in relation to COVID-19 virus.

The appointment of China-based XKX, which will be non-exclusive, is dependent on the successful completion of the clinical trials that E-Mo Biology Inc.(“EBI”) will be undertaking to evaluate the effectiveness of the polio vaccines in preventing COVID-19 infections.

HWGB Biotech had entered into a Memorandum of Agreement on 6 August 2020 (which was superseded by a Joint Venture Agreement on 14 August 2020) with E-Mo Biology Inc.(“EBI”) to collaborate whereby EBI shall undertake phase IV clinical trials for a new indication which proposes the use of existing poliomyelitis virus vaccines for prevention of the Diseases and the research and development, testing, registration, commercialization and other activities for the purposes of treating infectious disease, including vaccines, immunological treatment, diagnostic product development and any similar treatments against the Severe Acute Respiratory Syndrome Coronavirus pandemic and other relevant diseases (the “Diseases”) including but not limited to new indications which proposes the use of all types of existing poliomyelitis virus vaccines for prevention of COVID-19.

XKX is principally involved in research and development of preventive vaccines for human use, as well as the manufacturing, marketing and sales of preventive vaccines; XKX has the production facilities and is able to manufacture poliomyelitis vaccines, including different strains and formulation and dosage form systems of oral poliovirus (OPV), Oral Poliovirus (liquid) (OPVL) and Inactivated Poliovirus Vaccine (IPV) (“Polio Vaccines”) and the new indication which proposes the use of existing Polio Vaccines for prevention of COVID-19 virus; while HWGB Biotech is a distributor of biotechnology products, bioinformatics diagnostic tools, medical engineering equipment along with software developments and tools. It also patents all original products and by-products, technologies and software developed or sourced by HWGB.

Chief Executive Officer of HWGB, Dato’ Aaron Lim expressed: “We are taking the step in signing this MoU as we feel that time is of the essence due to the spread of COVID-19 and the impact it has on the economy and society. The MoU allows us to discuss more with a potential partner on the manufacturing of the polio vaccines should the clinical trials to be undertaken by EBI proves successful”.

“It also helps that XKX has the production facilities to manufacture poliomyelitis vaccines, including different strains, formulation and dosage form systems for oral poliovirus, oral poliovirus (liquid) and inactivated poliovirus vaccines as this will definitely quicken the process of distribution in Southeast Asia where COVID-19 infections have not abated”.

Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in Health Supplement, Biotechnology and Health Technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of Investment holdings; manufacturing of wire and cable and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wire and cable; and travel agent and tour related services.

For more information about HWGB Biotech, please visit and/or

Please also feel free to subscribe to our newsletter online to get latest exciting developments of our new ventures. Click on to subscribe.